redskins44

My take is that it is because there are a lot of estimations with the valuation of intangible assets. For example a specific drug patent certaintly has some value to a company but may be worth something completely different to another company and therefor would not be able to reasonably sell the asset at book or fair value. Thus it is not of the similar quality compared to machinary, cash, or other assets that are comparably valued by others.
Thats the way I view it, but I may be completely wrong.